Paragh György, Harangi Mariann
Debreceni Egyetem, Orvos-es Egészségtudományi Centrum, Altalános Orvostudományi Kar, 1. Belgyógyászati Klinika.
Orv Hetil. 2006 Mar 5;147(9):389-94.
The incidence of dyslipidemia is rising worldwide. Dyslipidemia combined with other factors represent the primary risk factors for the development of cardiovascular diseases. The National Cholesterol Education Program has recently updated the Adult Treatment Panel III guidelines and called for more intensive lipid lowering treatment, especially in patients at high risk for coronary heart disease. A statin and fibrate combination is a possible approach, moreover, niacin, particularly in combination with statins, might have a successful comeback. However, despite the existence of evidence-based treatment guidelines and effective antilipemic medications, recommended cardiovascular risk reduction rarely is achieved. This article summarises the mechanisms of action of available lipid lowering agents, their recommended dosing regiments and possible drug interactions.
全球血脂异常的发病率正在上升。血脂异常与其他因素共同构成了心血管疾病发生的主要危险因素。美国国家胆固醇教育计划最近更新了成人治疗小组第三次指南，呼吁采取更强化的降脂治疗，尤其是在冠心病高危患者中。他汀类药物与贝特类药物联合使用是一种可行的方法，此外，烟酸，特别是与他汀类药物联合使用时，可能会再次成为有效的药物。然而，尽管有循证治疗指南和有效的降脂药物，但推荐的心血管疾病风险降低目标却很少能够实现。本文总结了现有降脂药物的作用机制、推荐的给药方案以及可能的药物相互作用。
